Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)

被引：11
|
作者：
Schwartzberg, Lee S.
Franco, Sandra X.
Florance, Allison
O'Rourke, Lisa
Maltzman, Julie
Johnston, Stephen
机构：
来源：
ONCOLOGIST | 2010年 / 15卷 / 03期
关键词：
D O I：
10.1634/theoncologist.2009-0240erratum
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [41] Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
    Alvarado-Miranda, Alberto
    Lara-Medina, Fernando Ulises
    Munoz-Montano, Wendy R.
    Zinser-Sierra, Juan W.
    Galeana, Paula Anel Cabrera
    Garza, Cynthia Villarreal
    Benitez, Daniel Sanchez
    Rodriguez, Jesus Alberto Limon
    Salinas, Claudia Haydee Arce
    Guijosa, Alberto
    Arrieta, Oscar
    CURRENT ONCOLOGY, 2023, 30 (07) : 6097 - 6110
  • [42] First-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2
    Hortobagyi, Gabriel N.
    Stemmer, Salomon
    Campone, Mario
    Sonke, Gabe S.
    Arteaga, Carlos L.
    Paluch-Shimon, Shani
    Petrakova, Katarina
    Villanueva, Cristian
    Nusch, Arnd
    Grischke, Eva-Maria
    Chan, Arlene
    Jakobsen, Erik
    Marschner, Norbert
    Hart, Lowell L.
    Alba, Emilio
    Ohnstand, Hege O.
    Blau, Sibel
    Yardley, Denise A.
    Solovieff, Nadia
    Su, Faye
    Germa, Caroline
    Yap, Yoon-Sim
    CANCER RESEARCH, 2018, 78 (04)
  • [43] Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy
    Paul, D.
    Vukelja, S. J.
    Holmes, F. A.
    Blum, J.
    McIntyre, K. J.
    Kumar, A. R.
    Lindquist, D. L.
    Osborne, C. R.
    Sanchez, I. J.
    Goldschmidt, J. H.
    Wang, Y.
    Asmar, L.
    Lee, M. E.
    Wu, N.
    Logie, K.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2013, 73
  • [44] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [45] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Shimoi, Tatsunori
    Sagara, Yasuaki
    Hara, Fumikata
    Toyama, Tatsuya
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (03) : 340 - 346
  • [46] An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+Metastatic Breast Cancer
    Esteva, F. J.
    Franco, S. X.
    Hagan, M. K.
    Somer, R. A.
    Dombroski, C. S.
    Florance, A. M.
    Turner, S. J.
    Stein, S.
    Perez, A.
    CANCER RESEARCH, 2009, 69 (24) : 793S - 793S
  • [47] First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
    Tatsunori Shimoi
    Yasuaki Sagara
    Fumikata Hara
    Tatsuya Toyama
    Hiroji Iwata
    Breast Cancer, 2020, 27 : 340 - 346
  • [48] Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer
    Delea, Thomas E.
    Hawkes, Carol
    Amonkar, Mayur M.
    Lykopoulos, Konstantinos
    Johnston, Stephen R. D.
    BREAST CARE, 2013, 8 (06) : 429 - 437
  • [49] Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer
    Crown, J.
    Kennedy, M. J.
    Tresca, P.
    Marty, M.
    Espie, M.
    Burris, H. A.
    DeSilvio, M.
    Lau, M. R.
    Kothari, D.
    Koch, K. M.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2005 - 2011
  • [50] Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
    Zembryki, D.
    Gomez, H.
    Koehler, M.
    Koehler, M.
    Johnston, S.
    Pippen, J.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345